Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Lomustine × Other solid neoplasm × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 71 Lymphoid 11 Sarcoma 7 Other hematologic neoplasm 4 Thoracic 2 Dermatologic 2 Plasma cell 1 Other solid neoplasm 1 Genitourinary 1 Gastrointestinal 1 Breast 1

Conditions

Interventions

Cisplatin 129 pembrolizumab 106 Carboplatin 104 Paclitaxel 87 Injections 86 Pemetrexed 81 Gemcitabine 73 Irinotecan 64 Cyclophosphamide 61 Docetaxel 58 Nivolumab 57 Bevacizumab 53 Fluorouracil 44 Capecitabine 42 Oxaliplatin 41 atezolizumab 39 Leucovorin 38 tislelizumab 36 Etoposide 34 toripalimab 28 fludarabine 27 Ipilimumab 27 Topotecan 24 Radiotherapy 24 durvalumab 23 Drug Therapy 23 olaparib 21 Vincristine 21 Sorafenib 21 spartalizumab 20

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05898451 2023-06-12

R-2

Refnot-Pharm Ltd

Phase 2 Completed

Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡